{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:41:33Z","timestamp":1794346893812,"version":"4.9.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institutes of Mental Health","doi-asserted-by":"crossref","award":["R01MH124590"],"award-info":[{"award-number":["R01MH124590"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institutes of Mental Health","doi-asserted-by":"crossref","award":["R01MH124590"],"award-info":[{"award-number":["R01MH124590"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institutes of Mental Health","doi-asserted-by":"crossref","award":["R01MH124590"],"award-info":[{"award-number":["R01MH124590"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institutes of Mental Health","doi-asserted-by":"crossref","award":["R01MH124590"],"award-info":[{"award-number":["R01MH124590"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institutes of Mental Health","doi-asserted-by":"crossref","award":["R01MH124590"],"award-info":[{"award-number":["R01MH124590"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institutes of Mental Health","doi-asserted-by":"crossref","award":["R01MH124590"],"award-info":[{"award-number":["R01MH124590"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institutes of Mental Health","doi-asserted-by":"crossref","award":["R01MH124590"],"award-info":[{"award-number":["R01MH124590"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institutes of Mental Health","doi-asserted-by":"crossref","award":["R01MH124590"],"award-info":[{"award-number":["R01MH124590"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["Innovation in Regulatory Science"],"award-info":[{"award-number":["Innovation in Regulatory Science"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>HIV molecular epidemiology (HIV ME) can support the early detection of emerging clusters of new HIV infections by combining HIV sequence data routinely obtained during the clinical treatment of people living with HIV with behavioral, geographic, and sociodemographic information. While information about emerging clusters promises to facilitate HIV prevention and treatment efforts, the use of this data also raises several ethical concerns. We sought to assess how those working on the frontlines of HIV ME, specifically public health practitioners (PHPs) and researchers, prioritized these issues.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ethical issues were identified through literature review, qualitative in-depth interviews, and stakeholder engagement. PHPs and researchers using HIV ME prioritized the issues using best\u2013worst scaling (BWS). A balanced incomplete block design was used to generate 11 choice tasks each consisting of a sub-set of 5 ethical concerns. In each task, respondents were asked to assess the most and least concerning issue. Data were analyzed using conditional logit, with a Swait-Louviere test of poolability. Latent class analysis was then used to explore preference heterogeneity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 57 respondents completed the BWS experiment May\u2013June 2023 with the Swait-Louviere test indicating that researchers and PHPs could be pooled (<jats:italic>p<\/jats:italic>\u2009=\u20090.512). Latent class analysis identified two classes, those highlighting \u201cHarms\u201d (<jats:italic>n<\/jats:italic>\u2009=\u200929) (prioritizing concerns about potential risk of legal prosecution, individual harm, and group stigma) and those highlighting \u201cUtility\u201d (<jats:italic>n<\/jats:italic>\u2009=\u200928) (prioritizing concerns about limited evidence, resource allocation, non-disclosure of data use for HIV ME, and the potential to infer the directionality of HIV transmission). There were no differences in the characteristics of members across classes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The ethical issues of HIV ME vary in importance among stakeholders, reflecting different perspectives on the potential impact and usefulness of the data. Knowing these differences exist can directly inform the focus of future deliberations about the policies and practices of HIV ME in the United States.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-024-18881-4","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:01:30Z","timestamp":1716984090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prioritization of ethical concerns regarding HIV molecular epidemiology by public health practitioners and researchers"],"prefix":"10.1186","volume":"24","author":[{"given":"Anne L. R.","family":"Schuster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli","family":"Bollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Sugarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F. P.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"issue":"7","key":"18881_CR1","doi-asserted-by":"publisher","first-page":"e22449","DOI":"10.1371\/journal.pone.0022449","volume":"6","author":"MR Khanani","year":"2011","unstructured":"Khanani MR, Somani M, Rehmani SS, Veras NM, Salemi M, Ali SH. The spread of HIV in Pakistan: bridging of the epidemic between populations. PLoS One. 2011;6(7):e22449. https:\/\/doi.org\/10.1371\/journal.pone.0022449.","journal-title":"PLoS ONE"},{"issue":"9","key":"18881_CR2","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ526","volume":"61","author":"X Wang","year":"2015","unstructured":"Wang X, Wu Y, Mao L, et al. Targeting HIV prevention based on molecular epidemiology among deeply sampled subnetworks of men who have sex with men. Clin Infect Dis. 2015;61(9):1462\u20138. https:\/\/doi.org\/10.1093\/cid\/civ526.","journal-title":"Clin Infect Dis"},{"key":"18881_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/1471-2334-13-509","volume":"13","author":"JI Brooks","year":"2013","unstructured":"Brooks JI, Niznick H, Ofner M, Merks H, Angel JB. Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions. BMC Infect Dis. 2013;13:509. https:\/\/doi.org\/10.1186\/1471-2334-13-509.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"18881_CR4","doi-asserted-by":"publisher","first-page":"e1006895","DOI":"10.1371\/journal.ppat.1006895","volume":"14","author":"D K\u00fchnert","year":"2018","unstructured":"K\u00fchnert D, Kouyos R, Shirreff G, et al. Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. PLoS Pathog. 2018;14(2):e1006895. https:\/\/doi.org\/10.1371\/journal.ppat.1006895.","journal-title":"PLoS Pathog"},{"issue":"2","key":"18881_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/qai.0000000000000831","volume":"71","author":"T Panichsillapakit","year":"2016","unstructured":"Panichsillapakit T, Smith DM, Wertheim JO, Richman DD, Little SJ, Mehta SR. Prevalence of transmitted HIV drug resistance among recently infected persons in San Diego, CA 1996\u20132013. J Acquir Immune Defic Syndr. 2016;71(2):228\u201336. https:\/\/doi.org\/10.1097\/qai.0000000000000831.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"18881_CR6","doi-asserted-by":"publisher","first-page":"e21189","DOI":"10.1371\/journal.pone.0021189","volume":"6","author":"AF Poon","year":"2011","unstructured":"Poon AF, Aldous JL, Mathews WC, et al. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS One. 2011;6(6):e21189. https:\/\/doi.org\/10.1371\/journal.pone.0021189.","journal-title":"PLoS ONE"},{"issue":"6","key":"18881_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/infdis\/jiu560","volume":"211","author":"AF Poon","year":"2015","unstructured":"Poon AF, Joy JB, Woods CK, et al. The impact of clinical, demographic and risk factors on rates of HIV transmission: a population-based phylogenetic analysis in British Columbia, Canada. J Infect Dis. 2015;211(6):926\u201335. https:\/\/doi.org\/10.1093\/infdis\/jiu560.","journal-title":"J Infect Dis"},{"issue":"3","key":"18881_CR8","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1371\/journal.pmed.0050050","volume":"5","author":"F Lewis","year":"2008","unstructured":"Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med. 2008;5(3):e50. https:\/\/doi.org\/10.1371\/journal.pmed.0050050.","journal-title":"PLoS Med"},{"issue":"12","key":"18881_CR9","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/infdis\/jiy130","volume":"217","author":"M Ragonnet-Cronin","year":"2018","unstructured":"Ragonnet-Cronin M, Jackson C, Bradley-Stewart A, et al. Recent and rapid transmission of HIV among people who inject drugs in Scotland revealed through phylogenetic analysis. J Infect Dis. 2018;217(12):1875\u201382. https:\/\/doi.org\/10.1093\/infdis\/jiy130.","journal-title":"J Infect Dis"},{"issue":"320","key":"18881_CR10","doi-asserted-by":"publisher","first-page":"320ra2","DOI":"10.1126\/scitranslmed.aad1863","volume":"8","author":"O Ratmann","year":"2016","unstructured":"Ratmann O, van Sighem A, Bezemer D, et al. Sources of HIV infection among men having sex with men and implications for prevention. Sci Transl Med. 2016;8(320):320ra2. https:\/\/doi.org\/10.1126\/scitranslmed.aad1863.","journal-title":"Sci Transl Med"},{"issue":"10279","key":"18881_CR11","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/s0140-6736(21)00390-1","volume":"397","author":"C Beyrer","year":"2021","unstructured":"Beyrer C, Adimora AA, Hodder SL, et al. Call to action: how can the US Ending the HIV Epidemic initiative succeed? Lancet. 2021;397(10279):1151\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(21)00390-1.","journal-title":"Lancet"},{"issue":"9","key":"18881_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844\u20135. https:\/\/doi.org\/10.1001\/jama.2019.1343.","journal-title":"JAMA"},{"key":"18881_CR13","unstructured":"US Centers for Disease Control and Prevention. HIV cluster and outbreak detection and response. https:\/\/www.cdc.gov\/hiv\/programresources\/guidance\/cluster-outbreak\/index.html#:%7E:text=Molecular%20data%20analysis%20can%20help%20detect%20HIV%20clusters%20and%20outbreaks,had%20not%20been%20previously%20recognized. Accessed 20 Sept 2023."},{"key":"18881_CR14","unstructured":"US PLHIV Caucus. Open letter to the CDC networks of people living with HIV demand a moratorium on molecular HIV surveillance. https:\/\/actionnetwork.org\/forms\/open-letter-to-the-cdc-we-demand-a-moratorium-on-molecular-hiv-surveillance. Accessed 20 Sept 2023."},{"key":"18881_CR15","unstructured":"Presidential Advisory Council on HIV\/AIDS (PACHA). Molecular HIV surveillance and cluster detection and response resolution. https:\/\/files.hiv.gov\/s3fs-public\/2022-11\/PACHA-resolution-on-Molecular-HIV-Surveillance-Cluster-Detection-and-Response-10-17-22.pdf. Accessed 20 Sept 2023."},{"issue":"10","key":"18881_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/15265161.2020.1806373","volume":"20","author":"S Molldrem","year":"2020","unstructured":"Molldrem S, Smith AKJ. Reassessing the ethics of molecular HIV surveillance in the era of cluster detection and response: toward HIV data justice. Am J Bioeth. 2020;20(10):10\u201323. https:\/\/doi.org\/10.1080\/15265161.2020.1806373.","journal-title":"Am J Bioeth"},{"issue":"3","key":"18881_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.4081\/jphr.2017.992","volume":"6","author":"C Schairer","year":"2017","unstructured":"Schairer C, Mehta SR, Vinterbo SA, Hoenigl M, Kalichman M, Little S. Perceptions of molecular epidemiology studies of HIV among stakeholders. J Public Health Res. 2017;6(3):992. https:\/\/doi.org\/10.4081\/jphr.2017.992.","journal-title":"J Public Health Res"},{"issue":"3","key":"18881_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/23294515.2019.1601648","volume":"10","author":"CE Schairer","year":"2019","unstructured":"Schairer CE, Mehta SR, Vinterbo SA, Hoenigl M, Kalichman M, Little SJ. Trust and expectations of researchers and public health departments for the use of HIV molecular epidemiology. AJOB Empir Bioeth. 2019;10(3):201\u201313. https:\/\/doi.org\/10.1080\/23294515.2019.1601648.","journal-title":"AJOB Empir Bioeth"},{"issue":"3","key":"18881_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/coh.0000000000000538","volume":"14","author":"SR Mehta","year":"2019","unstructured":"Mehta SR, Schairer C, Little S. Ethical issues in HIV phylogenetics and molecular epidemiology. Curr Opin HIV AIDS. 2019;14(3):221\u20136. https:\/\/doi.org\/10.1097\/coh.0000000000000538.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"18881_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15265161.2020.1809550","volume":"20","author":"EJ Bernard","year":"2020","unstructured":"Bernard EJ, McClelland A, Cardell B, et al. We are people, not clusters! Am J Bioeth. 2020;20(10):1\u20134. https:\/\/doi.org\/10.1080\/15265161.2020.1809550.","journal-title":"Am J Bioeth"},{"issue":"10","key":"18881_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/15265161.2020.1806392","volume":"20","author":"S Rennie","year":"2020","unstructured":"Rennie S, Sullivan K, Dennis A. HIV molecular epidemiology: tool of oppression or empowerment? Am J Bioeth. 2020;20(10):44\u20137. https:\/\/doi.org\/10.1080\/15265161.2020.1806392.","journal-title":"Am J Bioeth"},{"issue":"10","key":"18881_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/15265161.2020.1806398","volume":"20","author":"M Watson","year":"2020","unstructured":"Watson M, Sweeney P. Furthering discussion of ethical implementation of HIV cluster detection and response. Am J Bioeth. 2020;20(10):24\u20136. https:\/\/doi.org\/10.1080\/15265161.2020.1806398.","journal-title":"Am J Bioeth"},{"key":"18881_CR23","unstructured":"Whitehead S. Critics worry government surveillance of HIV may hurt more than it helps. https:\/\/kffhealthnews.org\/news\/article\/government-surveillance-hiv-criminalization-privacy-data-concerns\/. Accessed 23 Sept 2023."},{"key":"18881_CR24","unstructured":"Nelson B. Questioning the benefits of molecular surveillance. https:\/\/www.poz.com\/article\/questioning-benefits-molecular-surveillance. Accessed 20 Sept 2023."},{"issue":"5 Suppl 1","key":"18881_CR25","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.amepre.2021.05.029","volume":"61","author":"AM Oster","year":"2021","unstructured":"Oster AM, Lyss SB, McClung RP, et al. HIV cluster and outbreak detection and response: the science and experience. Am J Prev Med. 2021;61(5 Suppl 1):S130-s142. https:\/\/doi.org\/10.1016\/j.amepre.2021.05.029.","journal-title":"Am J Prev Med"},{"issue":"2","key":"18881_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/qai.0000000000003179","volume":"93","author":"JM Bollinger","year":"2023","unstructured":"Bollinger JM, Geller G, May E, Brewer J, Henry LM, Sugarman J. Brief report: challenges in obtaining the informed perspectives of stakeholders regarding HIV molecular epidemiology. J Acquir Immune Defic Syndr. 2023;93(2):87\u201391. https:\/\/doi.org\/10.1097\/qai.0000000000003179.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"18881_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/09581596.2019.1582755","volume":"30","author":"A McClelland","year":"2020","unstructured":"McClelland A, Guta A, Gagnon M. The rise of molecular HIV surveillance: Implications on consent and criminalization. Crit Public Health. 2020;30(4):487\u201393. https:\/\/doi.org\/10.1080\/09581596.2019.1582755.","journal-title":"Crit Public Health"},{"issue":"1","key":"18881_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2105\/ajph.2011.300297","volume":"102","author":"LM Lee","year":"2012","unstructured":"Lee LM, Heilig CM, White A. Ethical justification for conducting public health surveillance without patient consent. Am J Public Health. 2012;102(1):38\u201344. https:\/\/doi.org\/10.2105\/ajph.2011.300297.","journal-title":"Am J Public Health"},{"key":"18881_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/1468-0009.12663","volume":"101","author":"SS Molldrem","year":"2023","unstructured":"Molldrem SS, Anthony KJ, McClelland A. Advancing dialogue about consent and molecular HIV surveillance in the United States: four proposals following a federal advisory panel\u2019s call for major reforms. Milbank Q. 2023;101:1033\u201346. https:\/\/doi.org\/10.1111\/1468-0009.12663.","journal-title":"Milbank Q"},{"issue":"1","key":"18881_CR30","doi-asserted-by":"publisher","first-page":"19119","DOI":"10.1038\/s41598-021-96743-4","volume":"11","author":"CJ Guerrini","year":"2021","unstructured":"Guerrini CJ, Crossnohere NL, Rasmussen L, Bridges JFP. A best-worst scaling experiment to prioritize concern about ethical issues in citizen science reveals heterogeneity on people-level v. data-level issues. Sci Rep. 2021;11(1):19119. https:\/\/doi.org\/10.1038\/s41598-021-96743-4.","journal-title":"Sci Rep"},{"key":"18881_CR31","doi-asserted-by":"crossref","unstructured":"Louviere JJ, Flynn TN, Marley AAJ. Best-worst scaling: theory, methods and applications.\u00a0Cambridge: Cambridge University Press; 2015.","DOI":"10.1017\/CBO9781107337855"},{"issue":"1","key":"18881_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jhealeco.2006.04.002","volume":"26","author":"TN Flynn","year":"2007","unstructured":"Flynn TN, Louviere JJ, Peters TJ, Coast J. Best\u2013worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171\u201389.","journal-title":"J Health Econ"},{"issue":"9","key":"18881_CR33","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/risa.12012","volume":"33","author":"S Erdem","year":"2013","unstructured":"Erdem S, Rigby D. Investigating heterogeneity in the characterization of risks using best worst scaling. Risk Anal. 2013;33(9):1728\u201348. https:\/\/doi.org\/10.1111\/risa.12012.","journal-title":"Risk Anal"},{"issue":"1","key":"18881_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13561-016-0080-z","volume":"6","author":"AC M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher AC, Kaczynski A, Zweifel P, Johnson FR. Experimental measurement of preferences in health and healthcare using best-worst scaling: an overview. Heal Econ Rev. 2016;6(1):1\u201314.","journal-title":"Heal Econ Rev"},{"issue":"4","key":"18881_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jval.2015.12.020","volume":"19","author":"JD van Dijk","year":"2016","unstructured":"van Dijk JD, Groothuis-Oudshoorn CG, Marshall DA, IJzerman MJ. An empirical comparison of discrete choice experiment and best-worst scaling to estimate stakeholders\u2019 risk tolerance for hip replacement surgery. Value Health. 2016;19(4):316\u201322. https:\/\/doi.org\/10.1016\/j.jval.2015.12.020.","journal-title":"Value Health"},{"issue":"12","key":"18881_CR36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/hec.3459","volume":"26","author":"N Krucien","year":"2017","unstructured":"Krucien N, Watson V, Ryan M. Is best-worst scaling suitable for health state valuation? A comparison with discrete choice experiments. Health Econ. 2017;26(12):e1\u201316. https:\/\/doi.org\/10.1002\/hec.3459.","journal-title":"Health Econ"},{"issue":"9","key":"18881_CR37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-022-01167-1","volume":"40","author":"IL Hollin","year":"2022","unstructured":"Hollin IL, Paskett J, Schuster ALR, Crossnohere NL, Bridges JFP. Best-worst scaling and the prioritization of objects in health: a systematic review. Pharmacoeconomics. 2022;40(9):883\u201399. https:\/\/doi.org\/10.1007\/s40273-022-01167-1.","journal-title":"Pharmacoeconomics"},{"key":"18881_CR38","doi-asserted-by":"publisher","first-page":"100466","DOI":"10.1016\/j.jocm.2023.100466","volume":"50","author":"ALR Schuster","year":"2024","unstructured":"Schuster ALR, Crossnohere NL, Campoamor NB, Hollin IL, Bridges JFP. The rise of best-worst scaling for prioritization: a transdisciplinary literature review. J Choice Model. 2024;50:100466. https:\/\/doi.org\/10.1016\/j.jocm.2023.100466.","journal-title":"J Choice Model"},{"issue":"4","key":"18881_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value Health"},{"key":"18881_CR40","unstructured":"The MaxDiff System: Technical Paper. Sawtooth software. 2020."},{"issue":"3","key":"18881_CR41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/002224379303000303","volume":"30","author":"J Swait","year":"1993","unstructured":"Swait J, Louviere J. The role of the scale parameter in the estimation and comparison of multinomial logit models. J Mark Res. 1993;30(3):305\u201314. https:\/\/doi.org\/10.1177\/002224379303000303.","journal-title":"J Mark Res"},{"issue":"3","key":"18881_CR42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/1536867X1301300312","volume":"13","author":"D Pacifico","year":"2013","unstructured":"Pacifico D, Yoo HI. lclogit: a stata command for fitting latent-class conditional logit models via the expectation-maximization algorithm. Stata J. 2013;13(3):625\u201339.","journal-title":"Stata J"},{"issue":"2","key":"18881_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40273-017-0575-4","volume":"36","author":"M Zhou","year":"2018","unstructured":"Zhou M, Thayer WM, Bridges JFP. Using latent class analysis to model preference heterogeneity in health: a systematic review. Pharmacoeconomics. 2018;36(2):175\u201387. https:\/\/doi.org\/10.1007\/s40273-017-0575-4.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"18881_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40271-013-0037-9","volume":"7","author":"K Deal","year":"2014","unstructured":"Deal K. Segmenting patients and physicians using preferences from discrete choice experiments. Patient. 2014;7(1):5\u201321. https:\/\/doi.org\/10.1007\/s40271-013-0037-9.","journal-title":"Patient"},{"key":"18881_CR45","unstructured":"Centers for Disease Control and Prevention. HIV and STD criminalization laws. https:\/\/www.cdc.gov\/hiv\/policies\/law\/states\/exposure.html. Accessed 1 Nov 2023."},{"key":"18881_CR46","unstructured":"U.S. Centers for Disease Control and Prevention. HIV CDR guidance for health departments. https:\/\/www.cdc.gov\/hiv\/programresources\/guidance\/hiv-cluster-detection-and-response-guidance\/index.html. Accessed 16 Feb 2024."},{"issue":"12","key":"18881_CR47","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/infdis\/jiaa107","volume":"222","author":"L Dawson","year":"2020","unstructured":"Dawson L, Benbow N, Fletcher FE, et al. Addressing ethical challenges in US-based HIV phylogenetic research. J Infect Dis. 2020;222(12):1997\u20132006. https:\/\/doi.org\/10.1093\/infdis\/jiaa107.","journal-title":"J Infect Dis"},{"key":"18881_CR48","unstructured":"Ryan B. H.I.V. groups warn of privacy risks in how C.D.C tracks virus samples. The New York Times. https:\/\/www.nytimes.com\/2024\/02\/09\/health\/hiv-molecular-surveillance-cdc.html?unlocked_article_code=1.UE0.kMYw.9KUUF4mLi9QU&smid=url-share.\u00a0Accessed 16 Feb 2024."},{"issue":"8","key":"18881_CR49","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.3390\/ijerph18084369","volume":"18","author":"KW Stone","year":"2021","unstructured":"Stone KW, Kintziger KW, Jagger MA, Horney JA. Public health workforce burnout in the COVID-19 response in the U.S. Int J Environ Res Public Health. 2021;18(8):4369. https:\/\/doi.org\/10.3390\/ijerph18084369.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"18881_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1377\/hlthaff.2022.01251","volume":"42","author":"JPCB Leider","year":"2023","unstructured":"Leider JPCB, Robbins M, Hare Bork R, Fraser M, Savoia E, Piltch-Loeb R, Koh HK. The exodus of state and local public health employees: separations started before and continued throughout COVID-19. Health Aff. 2023;42(3):338\u201348. https:\/\/doi.org\/10.1377\/hlthaff.2022.01251.","journal-title":"Health Aff"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18881-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-18881-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18881-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:03:24Z","timestamp":1716984204000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-18881-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["18881"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-18881-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The expert stakeholder engagement that guided survey development was deemed non-human subjects research by the Johns Hopkins School of Medicine (JHM #IRB IRB00354016). The survey was deemed non-human subject research by the Ohio State University College of Medicine Institutional Review Board (OSU IRB #2022E1207). As such, explicit informed consent was not required; consent was implied based on individuals\u2019\u00a0agreement to participate in the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS is a member of Merck KGaA\u2019s Ethics Advisory Panel and Stem Cell Research Oversight Committee; a member of IQVIA\u2019s Ethics Advisory Panel; a member of Aspen Neurosciences Clinical Advisory Panel; a member of a Merck Data Monitoring Committee; and a consultant to Biogen. None of these activities are related to the material discussed in this article. SJL receives funding to her institution from Gilead Sciences and served as a consultant to Hookipa Biotech. None of these activities are related to the material discussed in this article. TS has a research grant with ViiV Healthcare, but that research is not related to the material discussed in this article. ALRS, JMB, GG, SRM, JFPB have no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1436"}}